BMEAHealthcare · BiotechnologyThe 7 Wall Street analysts covering Biomea Fusion, Inc. hold a median 12-month price target of $6 — +838.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Biomea Fusion, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Momentum (15): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BMEA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +838.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Oct 2026 | Citizens | Reiterates | Market Outperform | $7.00 |
| 14 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $4.00 |
| 7 Oct 2026 | Brookline Capital | Initiates | Buy | $10 |
| 5 May 2026 | Citizens | Initiates | Market Outperform | $9.00 |
| 5 May 2026 | Citizens | Initiates | Market Outperform | — |
| 28 Apr 2026 | D. Boral Capital | Maintains | Buy | $12 |
| 28 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2026 | Citigroup | Maintains | Buy | — |
| 25 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 13 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 10 Nov 2025 | Citigroup | Maintains | Buy | — |
| 5 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Aug 2025 | Jefferies | Initiates | Buy | — |
| 11 Aug 2025 | Citigroup | Maintains | Buy | — |
| 6 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Aug 2025 | Scotiabank | Maintains | Sector Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BMEA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Biomea Fusion, Inc. returned −51.9% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 81% of US stocks
Cheaper than 24% of US stocks
Cheaper than 64% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biomea Fusion, Inc. has a market value of $46.4M and an enterprise value of $12.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$32.5M.
Free cash flow in the twelve months to 30 June 2026: −$47.2M.
Trailing P/E: −0.5×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Biomea Fusion, Inc. employs 37 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Biomea Fusion, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Benzinga reported that U.S. stock futures were mixed Wednesday morning, while Dow futures gained around 150 points. The headline identifies State Street, Fastenal and other stocks moving lower in pre-market trading.
Why it matters — The excerpt gives no BMEA-specific news or information, so it provides little direct context for BMEA watchers.
Biomea Fusion reported top-line results from a 28-day Phase Ib multiple ascending-dose study of BMF-650, an investigational oral small-molecule GLP-1 receptor agonist for weight management. The company said weight reduction occurred across active-treatment cohorts and gastrointestinal adverse events were mild or moderate.
Why it matters — The results provide an early update on BMF-650’s weight-management activity and tolerability, areas of interest to BMEA watchers.
Seeking Alpha published a transcript discussing Biomea Fusion’s BMF-650 Phase I topline results and the potential to separate gastrointestinal side effects from weight loss.
Why it matters — The discussion concerns early-stage BMF-650 findings and a potential distinction between gastrointestinal effects and weight-loss outcomes that may interest BMEA watchers.
Biomea Fusion reported Phase 1 GLP-131 trial results for investigational oral GLP-1 receptor agonist BMF-650, citing consistent weight reduction across five multiple-ascending-dose cohorts over four weeks and encouraging tolerability, including at 400 mg once daily after one titration step.
Why it matters — The early clinical findings provide BMEA watchers with an update on BMF-650’s observed weight reduction and tolerability.
Biomea Fusion announced that it will report Phase I results for BMF-650, its next-generation oral small-molecule GLP-1 receptor agonist. The company will host a conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT).
Why it matters — BMEA watchers can follow the scheduled presentation for an update on the clinical program for BMF-650.
The 7 Wall Street analysts covering Biomea Fusion, Inc. have a median 12-month price target of $6, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Biomea Fusion, Inc., 6 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biomea Fusion, Inc. 46 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Biomea Fusion, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +838.2% from the last close, and Ticker Nerd's factor model ranks Biomea Fusion, Inc. 46 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Biomea Fusion, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMEA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
Biomea Fusion, Inc. returned -51.9% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases.
The most recent item we track (Benzinga, 14 Oct 2026): "State Street, Fastenal And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session". Benzinga reported that U.S. stock futures were mixed Wednesday morning, while Dow futures gained around 150 points. The headline identifies State Street, Fastenal and other stocks moving lower in pre-market trading.
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases. Its current pipeline centers on icovamenib, a menin inhibitor being studied across multiple diabetes programs, and BMF-650, an oral GLP-1 receptor agonist in development for obesity. The company’s work is built around covalent chemistry and precision drug design, with an emphasis on therapies intended to address biologically defined patient groups. Biomea Fusion Inc. also explores applications in genetically defined cancers through its broader small-molecule research platform. Headquartered in San Carlos, California, Biomea Fusion Inc. plays a role in the biopharmaceutical market as a developer of investigational treatments aimed at challenging endocrine and metabolic conditions.
CEO Dr. Michael J. M. Hitchcock Ph.D. · 37 employees · United States · https://biomeafusion.com
